The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Collaborative projects can include investigators within one consortium, across consortia, and/or may include investigators who are not currently supported by the DCB research programs listed above but are collaborating with a member of a DCB led or co-led consortium (i.e. Associate Members). The programmatic goals of each research program may differ; therefore, it is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.
Collaborative projects must include at least one investigator not named as key personnel on the parent award who brings unique expertise that is required for the proposed project. The proposed research plan must be within the overall scope of the active parent U54, U24, U01, R37 and/or R01 award and align with the mission of the Division of Cancer Biology. All potential applicants are highly encouraged to contact their NCI Program Director to discuss the planned collaboration and application.